Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 17/20 | 0.64 |
| ▸ | CA12 | O43570 | 15/20 | 0.64 |
| ▸ | CA9 | Q16790 | 15/20 | 0.64 |
| ▸ | CA1 | P00915 | 15/20 | 0.64 |
| ▸ | CA4 | P22748 | 7/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 7/20 | 0.64 |
| ▸ | CA5A | P35218 | 7/20 | 0.54 |
| ▸ | CA7 | P43166 | 7/20 | 0.54 |
| ▸ | CA5B | Q9Y2D0 | 7/20 | 0.54 |
| ▸ | CA6 | P23280 | 6/20 | 0.54 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.54 |
| ▸ | CA3 | P07451 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL202948 | 0.81 | CA2 (0.81) | CA2CA12CA9CA1CA4 | |
| SCHEMBL6335571 | 0.78 | CA2 (0.61) | CA2CA12CA9CA1CA4 | |
| SCHEMBL6019009 | 0.78 | CA2 (1.00) | CA2CA12CA9CA1CA4 | |
| SCHEMBL329973 | 0.78 | CA2 (0.88) | CA2CA12CA9CA1CA4 | |
| SCHEMBL1066580 | 0.78 | CA2 (1.00) | CA2CA12CA9CA1CA4 | |
| Ammonia Solution, Strong SCHEMBL27578396 | 0.76 | CA2 (0.84) | CA2CA12CA9CA1CA4 | |
| SCHEMBL17161292 | 0.75 | F2 (0.43) | CA2CA12CA9CA1CA4 | |
| SCHEMBL4840191 | 0.75 | LMNA (0.54) | CA2CA12CA9CA1CA4 | |
| SCHEMBL3274288 | 0.75 | ALDH1A1 (0.50) | CA2CA12CA9CA1CA4 | |
| SCHEMBL3123896 | 0.75 | ENPP2 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-31 | — | — | US | claimed |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-06 | — | — | US | claimed |
| WO-2017035114-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | WO | claimed |
| US-20170057929-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | US | claimed |
| WO-2013034780-A2 | PROCESS FOR THE PREPARATION OF ESTETROL AND RELATED COMPOUNDS | CRYSTAL PHARMA, S.A.U. (ES) | 2013-03-14 | — | — | WO | claimed |
| US-20120077779-A1 | Inhibitors of Fibroblast Activation Protein Alpha | TRUSTEES OF TUFTS COLLEGE (US) | 2012-03-29 | — | — | US | claimed |
| US-20090221818-A1 | Inhibitors of Fibroblast Activation Protein Alpha | TRUSTEES OF TUFTS COLLEGE (US) | 2009-09-03 | — | — | US | claimed |
| EP-1898899-A4 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN ALPHA | TUFTS COLLEGE (US) | 2009-07-29 | — | — | EP | claimed |
| CN-101247799-A | Inhibitors of fibroblast activation protein alpha | TUFTS COLLEGE (US) | 2008-08-20 | — | — | CN | claimed |
| EP-1898899-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN ALPHA | TRUSTEES OF TUFTS COLLEGE (US) | 2008-03-19 | — | — | EP | claimed |
| US-20050130228-A1 | Dosing form for a polymer support, use of said dosing form in organic chemical synthesis and method for production of said dosing form | H. LUNDBECK A/S (DK) | 2005-06-16 | — | — | US | claimed |
| EP-1098659-A4 | LIBRARIES OF POLYHYDROXAMATES AND THEIR ANALOGS | METAPHORE INC (US) | 2004-11-24 | — | — | EP | claimed |
| US-20030138847-A1 | Dosing form for a polymer support, use of said dosing form in organic chemical synthesis and method for production of said dosing form | H. LUNDBECK A/S (DK) | 2003-07-24 | — | — | US | claimed |
| CN-1427743-A | Dosage forms of polymeric carriers, their use in organic chemical synthesis and process for producing said dosage forms | LONDBERK AS H (DK) | 2003-07-02 | — | — | CN | claimed |
| EP-1268050-A2 | DOSING FORM FOR A POLYMER SUPPORT, USE OF SAID DOSING FORM IN ORGANIC CHEMICAL SYNTHESIS AND METHOD FOR PRODUCTION OF SAID DOSING FORM | H. Lundbeck A/S (DK) | 2003-01-02 | — | — | EP | claimed |
| WO-2001068598-A2 | DOSING FORM FOR A POLYMER SUPPORT, USE OF SAID DOSING FORM IN ORGANIC CHEMICAL SYNTHESIS AND METHOD FOR PRODUCTION OF SAID DOSING FORM | H. LUNDBECK A/S (DK) | 2001-09-20 | — | — | WO | claimed |
| EP-1098659-A2 | LIBRARIES OF POLYHYDROXAMATES AND THEIR ANALOGS | Metaphore, Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004868-A2 | LIBRARIES OF POLYHYDROXAMATES AND THEIR ANALOGS | METAPHORE, INC. (US) | 2000-02-03 | — | — | WO | claimed |
| US-4883797-A | CARDIOVASCULAR PROPERTIES; INCREASING CEREBRAL FLOW | FERRER INTERNACIONAL, S.A. (ES) | 1989-11-28 | — | — | US | claimed |
| EP-0097340-A2 | Piperazine derivatives, a process for preparing them and pharmaceutical compositions | FERRER INTERNACIONAL, S.A. (ES) | 1984-01-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | CA2 1286/4885CA12 4094/4885CA9 3364/4885 |
| US-20170057929-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | CA2 1288/4885CA12 4090/4885CA9 3361/4885 |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | CNR1, GPR119, CNR2 | CA2 1288/4885CA12 4090/4885CA9 3361/4885 |
| US-20120077779-A1 | Inhibitors of Fibroblast Activation Protein Alpha | FIBP, FAP, BCAP31 | CA2 697/4885CA12 1787/4885CA9 837/4885 |
| US-20090221818-A1 | Inhibitors of Fibroblast Activation Protein Alpha | FIBP, FAP, BCAP31 | CA2 697/4885CA12 1787/4885CA9 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.